MOTS-c vs SS-31 (Elamipretide) — Two Mitochondrial Peptides, Two Mechanisms

MOTS-c and SS-31 (elamipretide) are the two mitochondrial-targeted peptides with substantial published research records, and they're almost completely different molecules. One is a 16-amino-acid peptide encoded by the mitochondrial genome itself; the other is a 4-amino-acid synthetic designed to bind cardiolipin in the inner membrane. They target the same organelle through entirely different mechanisms. This is the research comparison for UAE peptide researchers choosing between them.

1. The molecular biology — completely different molecules

MOTS-c

Discovered by Pinchas Cohen's lab at USC and published in Cell Metabolism (Lee et al. 2015), MOTS-c is a 16-amino-acid peptide whose remarkable feature is that it's encoded by an open reading frame inside the mitochondrial 12S rRNA gene. Mitochondria, until this discovery, were thought to encode only 13 proteins. MOTS-c was the first of a small family of mitochondrial-derived peptides (Humanin came earlier; MOTS-c was the second; SHLPs followed). The peptide translocates from the mitochondrion into the cytoplasm and the nucleus depending on metabolic state — it's a stress-response signal.

SS-31 (elamipretide)

Developed by Hazel Szeto's lab at Cornell and now commercialised by Stealth BioTherapeutics, SS-31 is a 4-amino-acid synthetic peptide: D-Arg-2',6'-Dmt-Lys-Phe-NH2. Its defining feature is selective accumulation in the inner mitochondrial membrane, where it binds cardiolipin (a phospholipid specific to mitochondria). The peptide carries no net charge at physiological pH but accumulates in the inner membrane through electrostatic interactions — a unique pharmacokinetic.

2. The molecular targets — different sites in the mitochondrion

3. The published evidence — depth differs by compound

MOTS-c evidence map

• Lee 2015 (Cell Metab): Foundational discovery paper. AMPK activation, improved glucose tolerance, prevention of diet-induced obesity in mouse.
• Reynolds 2021 (Nat Commun): MOTS-c as exercise mimetic in aged mouse model — running endurance ~70% greater than vehicle.
• Kim 2019 (Physiol Rep): Single-dose human pharmacokinetic + safety study; favourable tolerability.
• Yoshino 2018 (Cell Metab): Mitochondrial peptide family review.

SS-31 evidence map

• Multiple Stealth BioTherapeutics Phase 2/3 trials in primary mitochondrial myopathy: mixed results — some endpoints met, some not. The compound progressed to FDA orphan designation in this indication.
• Barth syndrome (TAZPOWER trial): Some functional improvement; not statistically definitive on primary endpoint.
• Heart failure, ischaemia-reperfusion injury, and dry AMD trials: Smaller; mixed results.
• Preclinical record: Two-hundred-plus publications across cardiac, renal, neurological, and aging models.

4. The dosing and route comparison

SS-31 trial doses (~40 mg/day) are substantially higher than MOTS-c research doses on a per-mg basis. The compound economics differ accordingly. The full MOTS-c protocol breakdown sits in our MOTS-c protocol research writeup.

5. Mechanistic complementarity — could they stack?

The mechanisms are non-overlapping:

• MOTS-c sends a signal into the cytoplasm and nucleus → AMPK activation → enhanced fuel substrate handling at the whole-cell level
• SS-31 sits at the inner mitochondrial membrane → stabilises the local environment where ATP is actually made

One drives upstream metabolic signalling; the other improves the machinery's efficiency. Stacking them is mechanistically defensible. There are no published combination trials. Researchers running combination protocols inject the two at different times (e.g., MOTS-c morning, SS-31 evening) and rotate sites.

6. The practical decision for UAE researchers

Choose MOTS-c if:

• You're researching exercise-mimetic, metabolic, or longevity endpoints
• Cost efficiency at research-grade pricing matters (10 mg vials at lower per-mg cost)
• You want the broader mechanistic claim set (AMPK pathway is involved in many downstream effects)

Choose SS-31 if:

• You're researching cardiac, neurological, or primary mitochondrial dysfunction endpoints
• You want the deeper clinical trial documentation
• The cardiolipin-binding mechanism aligns with your specific research question

Stack both if:

• You're running a comprehensive mitochondrial protocol and want both upstream signalling + downstream machinery support
• You accept that the combination is mechanism-based synthesis, not trial-validated

7. The reconstitution math — MOTS-c

REVIVE LAB UAE stocks MOTS-c in 10 mg lyophilised vials. Standard reconstitution:

• 10 mg + 2 mL bac water = 5 mg/mL
• 3 mg dose: 0.6 mL = 60 U-100 units
• 5 mg dose: 1.0 mL = 100 U (full syringe)
• ~10 days per vial at 1 mg/day; ~3-4 days at 3 mg/day

8. UAE supply context

MOTS-c is stocked at REVIVE LAB UAE in HPLC-verified 10 mg vials with lot-level COA. SS-31 (elamipretide) is research-grade material with a smaller global supply chain due to Stealth's commercial development; availability varies by lot.

MOTS-c UAE ships same-day on Dubai orders before 3 PM, 24 hours nationwide.

9. The summary

• MOTS-c: 16 aa, mtDNA-encoded, AMPK activator, exercise mimetic, broader mechanistic claims.
• SS-31: 4 aa synthetic, cardiolipin binder, ETC stabiliser, deeper clinical trial record in primary mitochondrial disease.
• Non-overlapping mechanisms — stacking is defensible though not trial-validated.
• MOTS-c dose: ~3 mg/day SC at standard research workflow.
• REVIVE LAB UAE stocks MOTS-c in HPLC-verified 10 mg vials.